Arno Amann1, Normann Steiner, Eberhard Gunsilius. 1. Department of Internal Medicine V (Haematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria, arno.amann@uki.at.
Abstract
BACKGROUND: Recurrent epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients significantly decreases their quality of life. Treatment in therapy refractory patients is limited although various options have been tested so far. CASE REPORT: Herein, one patient is described that was treated for HHT for over 20 years with only intermediate benefits. As epistaxis duration and frequency increased continuously, bevacizumab 5 mg/kg was administered every 2 weeks. During the time of treatment (six doses) and up to 3 month afterwards clinical symptoms, blood pressure, cardiac output, pulmonary arterial hypertension (PAH), bleeding duration and frequency were assessed as criteria for treatment benefit. RESULTS: Duration and frequency of epistaxis decreased immediately after the first application resulting in reduced need of blood transfusions. After completion of six cycles, a further decrease in frequency and duration of bleeding was noted. Cardiac output and PAH decreased or remained stable, respectively, during time and after treatment. No increase in blood pressure could be found but a significant increase in heart rate was experienced after completion of all six applications. Unfortunately, the patient died due to a cerebral abscess. CONCLUSION: Bevacizumab led to an improvement of HHT related epistaxis, refractory to other treatments.
BACKGROUND: Recurrent epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients significantly decreases their quality of life. Treatment in therapy refractory patients is limited although various options have been tested so far. CASE REPORT: Herein, one patient is described that was treated for HHT for over 20 years with only intermediate benefits. As epistaxis duration and frequency increased continuously, bevacizumab 5 mg/kg was administered every 2 weeks. During the time of treatment (six doses) and up to 3 month afterwards clinical symptoms, blood pressure, cardiac output, pulmonary arterial hypertension (PAH), bleeding duration and frequency were assessed as criteria for treatment benefit. RESULTS: Duration and frequency of epistaxis decreased immediately after the first application resulting in reduced need of blood transfusions. After completion of six cycles, a further decrease in frequency and duration of bleeding was noted. Cardiac output and PAH decreased or remained stable, respectively, during time and after treatment. No increase in blood pressure could be found but a significant increase in heart rate was experienced after completion of all six applications. Unfortunately, the patient died due to a cerebral abscess. CONCLUSION:Bevacizumab led to an improvement of HHT related epistaxis, refractory to other treatments.
Authors: Haneen Sadick; Wolfgang F Bergler; Jasmina Oulmi-Kagermann; Ramin Naim; Maliha Sadick; Karl Hörmann; Frank Riedel Journal: Arch Med Res Date: 2005 Sep-Oct Impact factor: 2.235
Authors: S Gaillard; S Dupuis-Girod; F Boutitie; S Rivière; S Morinière; P-Y Hatron; G Manfredi; P Kaminsky; A-L Capitaine; P Roy; F Gueyffier; H Plauchu Journal: J Thromb Haemost Date: 2014-07-29 Impact factor: 5.824
Authors: H Fukushima; T Mitsuhashi; T Oto; Y Sano; K F Kusano; K Goto; M Okazaki; H Date; Y Kojima; H Yamagishi; T Takahashi Journal: Am J Transplant Date: 2013-10-24 Impact factor: 8.086